EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors

T Jelinek iD, D Zihala, T Sevcikova, A Anilkumar Sithara iD, V Kapustova, H Sahinbegovic, O Venglar, L Muronova, L Broskevicova, S Nenarokov, D Bilek, T Popkova iD und 10 weitere

Leukemia · 2024

DOI: 10.1038/s41375-024-02206-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2024. Verfasst von T Jelinek und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Multiple Myeloma, High-Throughput Nucleotide Sequencing, Tumor Microenvironment. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council), EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj), Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors ( N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2.4, p = 0.011) using data from a large CoMMpass dataset. We identified downregulation of CXCR4 and enhanced cell proliferation, along with reduced expression of therapeutic targets (CD38, SLAMF7, GPRC5D, FCRH5), potentially explaining diminished efficacy of immunotherapy. Conversely, we identified significantly upregulated EZH2 and CD70 as potential future therapeutic options. For the first time, we report on the tumor microenvironment of EMM, revealing CD8+ T cells and NK cells as predominant immune effector cells using single-cell sequencing. Finally, this is the first longitudinal study in EMM revealing the molecular changes from the time of diagnosis to EMM relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHigh-Throughput Nucleotide SequencingTumor MicroenvironmentHumansMutationBiomarkers, TumorMaleFemaleMiddle AgedAgedBone MarrowPrognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
  • Department of Pathology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Nuclear Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Imaging Methods, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

ORCID-Profile: T Jelinek, A Anilkumar Sithara, T Popkova, M Havel, M Hrdinka, G Stracquadanio, M Simicek, R Hajek

Förderung

  • Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council)
  • EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj)
  • Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)

Zitieren

APA

Jelinek, T., Zihala, D., Sevcikova, T., Anilkumar Sithara, A., Kapustova, V., Sahinbegovic, H., Venglar, O., Muronova, L., Broskevicova, L., Nenarokov, S., Bilek, D., Popkova, T., Plonkova, H., Vrana, J., Zidlik, V., Hurnik, P., Havel, M., Hrdinka, M., Chyra, Z., …, & Hajek, R. (2024). Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. https://doi.org/10.1038/s41375-024-02206-w

Vancouver

Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024. doi:10.1038/s41375-024-02206-w

BibTeX
@article{Jelinek2024,
  author = {Jelinek, T and Zihala, D and Sevcikova, T and Anilkumar Sithara, A and Kapustova, V and Sahinbegovic, H and Venglar, O and Muronova, L and Broskevicova, L and Nenarokov, S and Bilek, D and Popkova, T and Plonkova, H and Vrana, J and Zidlik, V and Hurnik, P and Havel, M and Hrdinka, M and Chyra, Z and Stracquadanio, G and Simicek, M and Hajek, R},
  title = {Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors},
  journal = {Leukemia},
  year = {2024},
  doi = {10.1038/s41375-024-02206-w}
}
Kostenlos starten →